Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;268(9):3269-3282.
doi: 10.1007/s00415-020-09942-w. Epub 2020 May 30.

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

Lumei Kang #  1   2 , Yuyang Tian #  3   2 , Shilin Xu  3   2 , Hongping Chen  4   5
Affiliations
Review

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

Lumei Kang et al. J Neurol. 2021 Sep.

Abstract

Oxaliplatin (OXA) is a commonly used platinum-based chemotherapy drug for colorectal cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of OXA. OIPN can be divided into acute and chronic types according to clinical features and different mechanisms. The main clinical features of acute OIPN are cold-sensitive sensory symptoms and neuropathic pain in limbs. In addition to the above symptoms, chronic OIPN also produces autonomic nerve dysfunction. The most important mechanism involved in acute OIPN is the alteration of voltage-gated Na + channels, and nuclear DNA damage in chronic OIPN. There are some methods like reducing exposure to cold, calcium and magnesium salts, amifostine could be beneficial in acute OIPN prevention and dose modification, changing in schedule glutathione, duloxetine, selective serotonin reuptake inhibitors, carbonic anhydrase inhibitor in chronic OIPN prevention. Recent updates are provided in this article in relation to the clinical features, potential mechanisms, prevention and treatment of OIPN.

Keywords: Clinical features; Neuropathy; Oxaliplatin; Prevention and treatment.

PubMed Disclaimer

References

    1. Freddie B, Jacques F, Isabelle S et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 - DOI
    1. Cartwright E, Cunningham D (2017) The role of systemic therapy in resectable gastric and gastro-oesophageal junction cancer. Curr Treat Options Oncol 18:69. https://doi.org/10.1007/s11864-017-0510-0 - DOI - PubMed
    1. Hironaka S, Sugimoto N, Yamaguchi K et al (2016) S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17:99–108. https://doi.org/10.1016/S1470-2045(15)00410-6 - DOI - PubMed
    1. Dolan ME, El CO, Wheeler HE et al (2017) Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 23:5757–5768. https://doi.org/10.1158/1078-0432.CCR-16-3224 - DOI - PubMed - PMC
    1. Huang J, Zhao Y, Xu Y et al (2016) Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: a meta-analysis of randomized controlled trials. Oncotarget 7:34824–34831. https://doi.org/10.18632/oncotarget.9189 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources